Funding for this research was provided by:
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Fondation Philippe Chatrier
European Union Joint Program for Neurodegenerative Disorders
Received: 22 April 2020
Accepted: 10 July 2020
First Online: 20 July 2020
Ethics approval and consent to participate
: This study was approved by the Bichat Hospital Ethics Committee of Paris Diderot University.
: All patients signed an informed consent prior to inclusion in the study.
: JH is an investigator in several passive anti-amyloid immunotherapies and other clinical trials for Roche, Eisai, Lilly, Biogen, Astra-Zeneca, and Lundbeck. He is a member of the advisory boards for RAMAN Health, Roche, Protect, Netri, and Lilly.CP is a member of the International Advisory Boards of Lilly; is a consultant for Fujiribio, Alzhois, Neuroimmune, Ads Neuroscience, Roche, AgenT, and Gilead; and is involved as an investigator in several clinical trials for Roche, Esai, Lilly, Biogen, Astra-Zeneca, Lundbeck, and Neuroimmune.KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the present study.HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.EC and JD are investigators in several passive anti-amyloid immunotherapies and other clinical trials for Roche, Eisai, Lilly, Biogen, Astra-Zeneca, and Lundbeck.HV and EV are co-founders of ADX Neurosciences.FML, MT, ÅS, KH, AB, and EBA declare no disclosures.